Are you wondering whether Amvuttra (vutrisiran) injections help wild-type ATTR amyloidosis, or if the guidance your doctor received might be related to cost?
It's understandable to feel confused when you hear conflicting information. Currently, Amvuttra is being studied in clinical trials specifically for wild-type ATTR Show Full Answer
Are you wondering whether Amvuttra (vutrisiran) injections help wild-type ATTR amyloidosis, or if the guidance your doctor received might be related to cost?
It's understandable to feel confused when you hear conflicting information. Currently, Amvuttra is being studied in clinical trials specifically for wild-type ATTR amyloidosis, but it hasn't been as extensively proven for wild-type as it has for hereditary ATTR amyloidosis with polyneuropathy.
The medications that are FDA-approved and have strong evidence for treating wild-type ATTR amyloidosis affecting the heart include:
* Acoramidis (Attruby)
* Tafamidis (Vyndamax) - which you're already taking
* Tafamidis meglumine (Vyndaqel)
These are TTR stabilizers that help prevent the protein from misfolding and building up in the heart.
Vutrisiran works differently - it reduces the production of the transthyretin protein itself. While it's approved for hereditary ATTR amyloidosis with polyneuropathy, research is ongoing to determine its effectiveness specifically for wild-type disease.
Your doctor's comment about continuing "if you want" suggests there may not be strong evidence yet that Amvuttra provides additional benefit beyond Vyndamax for wild-type amyloidosis. This doesn't necessarily mean it's harmful, but the data supporting its use in wild-type specifically may be limited.
It's worth having a detailed conversation with your care team about what they hope to achieve with the combination therapy and whether there's emerging evidence supporting this approach for wild-type disease.
December 12, 2025
Join
Your Privacy Choices
